Increased CDA expression/activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy

PURPOSE: The cytidine analogues 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA-methyltransferase (DNMT1). This action is S-phase dependent. Hence, genetic factors that decrease the half-lives of these drugs could i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mahfouz, Reda Z, Jankowska, Ania, Ebrahem, Quteba, Gu, Xiaorong, Visconte, Valeria, Tabarroki, Ali, Terse, Pramod, Covey, Joseph, Chan, Kenneth, Ling, Yonghua, Engelke, Kory J., Sekeres, Mikkael A., Tiu, Ramon, Maciejewski, Jaroslaw, Radivoyevitch, Tomas, Saunthararajah, Yogen
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3577958/
https://ncbi.nlm.nih.gov/pubmed/23287564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-1722
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars